Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PriorixTM · 1 trial · 4 indications
Seroconversion was defined as the appearance of antibodies \[i.e. titer greater than or equal to (≥) the cut-off value\] in the sera of subjects seronegative \[i.e. titer below (\<) cut-off value\] before vaccination. Cut-off values were the following: Anti-measles concentration ≥ 150 milli-international units per milliliter (mIU/mL); Anti-mumps concentration ≥ 231 units per milliliter (U/mL); Anti-rubella concentration ≥ 4 international units per milliliter (IU/mL); Anti-VZV titer ≥ 1:4 dilution.
| Arm | Type | Description |
|---|---|---|
| PRIORIX-TETRA GROUP | EXPERIMENTAL | Healthy male and female subjects between, and including 11 and 24 months of age, who received one dose of Priorix-Tetra® vaccine at Day 0, administered subcutaneously in the deltoid region of the left upper arm. |
| PRIORIX + VARILRIX GROUP | ACTIVE_COMPARATOR | Healthy male and female subjects between, and including 11 and 24 months of age, who received one dose of Priorix™ vaccine together with one dose of Varilrix™ vaccine at Day 0, administered subcutaneously in the deltoid regions of the left or right upper arm, respectively. |
| Name | Type | Description |
|---|---|---|
| PriorixTM | BIOLOGICAL | Subcutaneous administration in left upper arm |
| VarilrixTM | BIOLOGICAL | Subcutaneous administration in right upper arm |
| Priorix-Tetra® | BIOLOGICAL | Subcutaneous injection in left upper arm |
Inclusion Criteria: * Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study. * A male or female between, and including 11 and 24 months of age, at the time of the vaccination. * Written informed ...
Priorix is a vaccine used for measles, as well as mumps, rubella, and varicella, based on its clinical trial in these conditions. It is being developed by GSK plc for the prevention of these infectious diseases.
Priorix is developed by GSK plc, a biopharma company listed on the stock exchange under the ticker GSK. The company is conducting clinical development of this vaccine for measles and related infectious diseases.
Priorix is in Phase 3 clinical development. It has completed one Phase 3 trial, which was an active-controlled study. The vaccine is investigational and not yet approved for use.
Priorix has one completed Phase 3 clinical trial, NCT00751348, which studied the immunogenicity and safety of a combined measles-mumps-rubella-varicella vaccine. The trial enrolled 475 participants in South Korea, including healthy volunteers aged 11 months and older.
No, Priorix is a vaccine, not a monoclonal antibody. Although the modality is listed as a monoclonal antibody in the data, the clinical trial description indicates it is a combined measles-mumps-rubella-varicella vaccine, which is a different type of biologic.